News
EVO
2.710
+0.74%
0.020
Weekly Report: what happened at EVO last week (0615-0619)?
Weekly Report · 3d ago
Evotec SE Discloses June 15 Share Sale by Management Board Member
TipRanks · 06/17 10:30
Evotec publishes company presentation outlining drug discovery strategy and outlook
PUBT · 06/16 19:26
Evotec executive board member Dr. Cord Dohrmann sells shares worth EUR 576,720
PUBT · 06/16 15:47
Weekly Report: what happened at EVO last week (0608-0612)?
Weekly Report · 06/15 09:48
Evotec publishes presentation for June 11, 2026 annual general meeting in Hamburg
PUBT · 06/12 09:17
Evotec publishes presentation for June 11, 2026 annual shareholder meeting
PUBT · 06/12 09:16
Evotec Reports Results of the Annual General Meeting 2026
PR Newswire · 06/11 16:02
Evotec appoints Dieter Weinand as supervisory board chair
PUBT · 06/11 13:31
Evotec shareholders adopt all AGM agenda items
PUBT · 06/11 13:30
Weekly Report: what happened at EVO last week (0601-0605)?
Weekly Report · 06/08 09:46
JPMorgan Chase lifts Evotec voting stake to 6.01% from 5.95%
PUBT · 06/04 08:47
Evotec names Rui Wang head of global in silico and AI unit
PUBT · 06/02 05:30
Weekly Report: what happened at EVO last week (0525-0529)?
Weekly Report · 06/01 09:48
Evotec reports 177,907,695 total voting rights outstanding
PUBT · 05/29 09:03
Evotec publishes shareholder letter for 2025
PUBT · 05/26 07:20
Weekly Report: what happened at EVO last week (0518-0522)?
Weekly Report · 05/25 09:50
Evotec board member Dr. Cord Dohrmann sells shares worth EUR 59,459
PUBT · 05/22 12:05
Evotec AG Earnings Call Balances Setback And Strategy
TipRanks · 05/20 05:12
U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide
Benzinga · 05/18 15:25
More
Webull provides a variety of real-time EVO stock news. You can receive the latest news about Evotec Ag through multiple platforms. This information may help you make smarter investment decisions.
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.